Trial
NCT03780634
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
Kaiping Central Hospital; Guangzhou No.12 People's Hospital
Condition
Hepatocellular Carcinoma
Intervention
HAIC
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-06